Cytokinetics Incorporated – Material Contracts Watch

from 10-K 2 pages Description of Director Compensation

from 10-K 4 pages Amendment No. 1 to the Collaboration and License Agreement

from 10-K 14 pages Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan Amended by the Board of Directors: February 6, 2013 Approved by Stockholders: May 22, 2013 Amended to Reflect the Reverse Stock Split: June 25, 2013 Amended and Restated by the Board of Directors: February 3, 2015 Approved by Stockholders: May 20, 2015 Amended and Restated by the Board of Directors: February 10, 2017 Approved by Stockholders: May 18, 2017 Amended and Restated by the Board of Directors: February 7, 2019 Approved by Stockholders: May 15, 2019 Amended to Reflect Separate Inducement Pool: May 14, 2020 Amended and Restated by the Board of Directors: February 18, 2021 Approved by the Stockholders: May 12, 2021 Amended and Restated to Increase Separate Inducement Pool: August 13, 2021 Amended and Restated by the Board of Directors: February 17, 2022 Approved by the Stockholders: May 10, 2022 Amended and Restated to Increase Separate Inducement Pool: May 26, 2022 Amended and Restated to Increase Separate Inducment Pool: March 1, 2023 Amended and Restated by the Board of Directors: February 17, 2025 Approved by the Stockholders: May 14, 2025 Amended and Restated to Increase Separate Inducment Pool: February 19, 2026

from 10-K 2 pages Description of Director Compensation

from 10-K 102 pages Confidential Execution Version Collaboration and License Agreement

from 10-K 6 pages Amendment to License and Collaboration Agreement

from 10-Q 4 pages Sixth Amendment to Lease

from 10-Q 4 pages August 13, 2024 • Base Salary: You Will Receive a Starting Annual Salary of $560,000 Which Will Be Paid Semi-Monthly in Accordance With the Company’s Normal Payroll Procedures. as an Exempt Employee, You Are Not Eligible for Overtime Pay

from 10-Q 18 pages Cytokinetics, Incorporated Common Stock Option Purchase Agreement

from 10-Q 47 pages Ck-586 Revenue Participation Right Purchase Agreement by and Between Cytokinetics, Incorporated and Royalty Pharma Investments 2019 Icav Dated as of May 22, 2024

from 10-Q 9 pages Amendment No. 1 to Revenue Participation Right Purchase Agreement

from 10-Q 22 pages Third Amendment and Consent

from 10-Q 4 pages March 28, 2024 • Base Salary: You Will Receive a Starting Annual Salary of $550,000 Which Will Be Paid Semi-Monthly in Accordance With the Company’s Normal Payroll Procedures. as an Exempt Employee, You Are Not Eligible for Overtime Pay

from 8-K 10 pages Cytokinetics, Incorporated 2015 Employee Stock Purchase Plan

from 10-Q 5 pages First_name-Middle_name-Last_name Address_line_1 Address_line_2 City, State-Country-Zipcode Award Number: Plan: Id: Option_number Equity_plan Employee_identifier Unless Otherwise Defined Herein, the Terms Defined in the Cytokinetics, Incorporated Amended and Restated 2004 Equity Incentive Plan (The “Plan”) Shall Have the Same Defined Meanings in This Performance Stock Unit Award Agreement (The “Agreement”). You Have Been Granted an Award of Performance Stock Units (“Psus”), Subject to the Terms and Conditions of the Plan and This Agreement, as Follows: Grant Number: Plan: Id: Date of Grant: Type of Award: Total Number of Psus Granted

from 10-Q 3 pages Description of Director Compensation

from 10-K 8 pages Fifth Amendment to Lease

from 8-K 13 pages Cytokinetics, Incorporated Executive Severance Plan and Summary Plan Description

from 10-K 59 pages Cytokinetics, Incorporated Shares of Common Stock (Par Value $0.001 Per Share) Amended and Restated Controlled Equity Offeringsm Sales Agreement

from 10-K 11 pages Second Amendment